---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-311402"
form_type: "8-K"
ticker: "RGEN"
cik: "0000730272"
company_name: "REPLIGEN CORP"
filed_at: "2026-07-22T12:56:58+00:00"
generated_at: "2026-07-22T13:00:29.711608+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Repligen to acquire BioLife Solutions for ~$1.5B; reports preliminary Q2 revenue growth of ~12%

## Summary
- Repligen to acquire BioLife for ~$1.5B; per share consideration $31.00 ($11.25 cash + 0.1442 RGEN shares).
- Deal expected to close Q4 2026; boards unanimously approved; subject to BLFS stockholder approval and HSR clearance.
- Expected to be accretive: at least $0.05 adjusted EPS in year one, at least $0.25 in year two.
- Repligen preliminary Q2 revenue growth ~12% (13% organic); BioLife preliminary Q2 revenue growth ~21% YoY.

## SEC filing metadata
- accession: 0001193125-26-311402
- form_type: 8-K
- ticker: RGEN
- cik: 0000730272
- company_name: REPLIGEN CORP
- filed_at: 2026-07-22T12:56:58+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/730272/000119312526311402/0001193125-26-311402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/730272/000119312526311402/d141685d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-311402
- JSON: https://secwatch.observer/filing/0001193125-26-311402.json
- Plain text: https://secwatch.observer/filing/0001193125-26-311402.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.